首页|康莱特注射液联合化疗在晚期肺癌患者中的应用效果

康莱特注射液联合化疗在晚期肺癌患者中的应用效果

扫码查看
目的:观察康莱特注射液联合化疗在晚期肺癌患者中的应用效果.方法:选取 2019 年 10 月至 2022 年 10 月该院收治的86 例晚期肺癌患者进行前瞻性研究,按随机数字表法将其分为观察组和对照组各 43 例.对照组予以化疗,观察组在对照组基础上联合康莱特注射液治疗,比较两组客观缓解率(ORR)、治疗前后肿瘤标志物[神经元特异性烯醇化酶(NSE)、糖类抗原 125(CA125)、癌胚抗原(CEA)]水平、肺功能指标[最大通气量(MVV)、用力肺活量(FVC)、第1秒用力呼气容积(FEVl)]水平、视觉模拟评分法(VAS)评分和治疗期间不良反应发生率.结果:观察组ORR为67.44%(29/43),高于对照组的44.19%(19/43),差异有统计学意义(P<0.05);治疗后,观察组NSE、CA125、CEA水平均低于对照组,差异有统计学意义(P<0.05);治疗后,观察组MVV、FVC、FEV1 水平均高于对照组,差异有统计学意义(P<0.05);治疗后,两组VAS评分均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);观察组不良反应发生率为 9.30%(4/43),低于对照组的 25.58%(11/43),差异有统计学意义(P<0.05).结论:康莱特注射液联合化疗应用于晚期肺癌患者可提高ORR和肺功能指标水平,降低肿瘤标志物水平、VAS评分和不良反应发生率,效果优于单纯化疗.
Application effects of Kanglaite injection combined with chemotherapy in patients with advanced lung cancer
Objective:To observe application effects of Kanglaite injection combined with chemotherapy in patients with advanced lung cancer.Methods:A prospective study was conducted on 86 patients with advanced lung cancer admitted to the hospital from October 2019 to October 2022.According to the random number table method,they were divided into observation group and control group,43 cases in each group.The control group was treated with chemotherapy,while the observation group was treated with Kanglaite injection on the basis of that of the control group.The objective remission rate(ORR),the tumor markers[neuron-specific enolase(NSE),carbohydrate antigen 125(CA125),carcinoembryonic antigen(CEA)]levels,the lung function indexes[maximum ventilation volume(MVV),forced vital capacity(FVC),forced expiratory volume in one second(FEV1)]levels,the visual analogue scale(VAS)score,and the incidence of adverse reactions during treatment were compared between the two groups before and after the treatment.Results:The ORR of the observation group was 67.44%(29/43),which was higher than 44.19%(19/43)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of NSE,CA125 and CEA in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of MVV,FVC and FEV1 in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the VAS scores of the two groups were lower than those before the treatment,that in the observation group was lower than that in the control group,and the differences were statistically significant(P<0.05).Further,the incidence of adverse reactions in the observation group was 9.30%(4/43),which was lower than 25.58%(11/43)in the control group,and the difference was statistically significant(P<0.05).Conclusions:Kanglaite injection combined with chemotherapy in the patients with advanced lung cancer can improve the levels of ORR and lung function indexes and reduce the levels of tumor markers,the VAS scores and the incidence of adverse reactions.Moreover,it is superior to single chemotherapy.

Advanced lung cancerChemotherapyKanglaite injectionTumor markerPainLung functionPain

崔志强、陈琼、闫志兴

展开 >

驻马店桐安肿瘤医院肿瘤科,河南 驻马店 463000

晚期肺癌 化疗 康莱特注射液 肿瘤标志物 疼痛 肺功能 疼痛

2024

中国民康医学
中国社会工作协会

中国民康医学

影响因子:0.649
ISSN:1672-0369
年,卷(期):2024.36(7)
  • 17